Erratum to “Glycemic Management in Adults With Type 1 Diabetes”

McGibbon, Angela; Adams, Lenley; Ingersoll, Karen S.; Kader, Tina; Tugwell, Barna

doi:10.1016/j.jcjd.2018.08.197

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding CSII use over the MDI, most physicians consider CSII as a means of improving glucose control when MDI failed to reach and maintain desired therapeutic targets. Some guidelines, like the National Institute of Clinical Excellence (NICE) in the UK [ 23 ] and Diabetes Canada [ 24 ], recommend the switch to CSII when basal-bolus MDI does not provide satisfactory results, either for persistently elevated HbA1c or recurrent hypoglycemia. However, ADA guidelines stated that CSII might be considered an option for all adults and youth with T1D who can safely manage the device [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Continuous subcutaneous insulin infusion is associated with a better glycemic control than multiple daily insulin injections without difference in diabetic ketoacidosis and hypoglycemia admissions among Emiratis with Type 1 diabetes

Almazrouei

Sharma²,

Afandi³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Aims To characterizes Emiratis patients with Type 1 diabetes (T1D) and compares outcomes between continuous subcutaneous insulin infusion (CSII) versus multiple daily insulin injections (MDI) users. The WHO-Five Well-Being Index (WHO-5) score was used to screen for depression. Methods In this cross-sectional study; sociodemographic, clinical characteristics and insulin replacement regimens were collected on patients with T1D between 2015–2018. Results 134 patients with mean age of 20.9±7.5 years were included. Females constitute 56.7% and 50.7% had diabetes duration of >10 years. Diabetic ketoacidosis (DKA) at presentation was reported in 46.3%. Average glycemic control over preceding 12months was satisfactory (less than 7.5%), suboptimal (7.5–9%), and poor (more than 9%) in 26.6%, 42.7% & 30.6% of the patients, respectively. Higher proportion of patients using CSII achieved satisfactory or suboptimal glycemic control compared to patients with MDI (P = 0.003). The latest median /IQR HbA1c was significantly lower (P = 0.041) in patients using CSII (8.2 /1.93%) compared to MDI (8.5/2.45%). There was no significant difference between two groups in DKA, severe hypoglycemia or total WHO-5 score. Conclusions CSII usage was associated with better glycemic control than MDI, although no difference in DKA and severe hypoglycemia. The overall glycemic control among Emiratis subjects with T1D is unsatisfactory and needs more rigorous patient counseling and education.

show abstract

Section: Discussionmentioning

confidence: 99%